# ADEPT-STAR-NET-1

Source: https://onco.cc/drugs/adept-star-net-1/  
OnCo record `adept-star-net-1` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ADEPT-STAR-NET-1 is an experimental cell therapy from Expression Therapeutics for neuroendocrine tumours. It has not yet been tested in people.

## Summary

ADEPT-STAR-NET-1 is Expression Therapeutics' lead cancer programme. The company reports that STAR-NET-1 gives unmodified gamma-delta T cells potent killing of SSTR2-positive cells in the femtomolar range and eradicated spheroids grown from gastroenteropancreatic neuroendocrine tumour samples in its laboratory model. No registered trial was found.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-04
- Also known as: STAR-NET-1
- Tags: pipeline
- Code: STAR-NET-1
- Modality: Engineered autologous gamma-delta T-cell therapy secreting a T-cell engager
- Mechanism: Autologous gamma-delta T cells programmed with the LENTeT gene transfer system to secrete STAR-NET-1, a CD3 epsilon by SSTR2 bispecific T-cell engager, so that both the infused cells and the patient's own T cells attack SSTR2-bearing tumour cells, as described by Expression Therapeutics.

## Sources

- Expression Therapeutics: neuroendocrine tumours: https://www.expressiontherapeutics.com/therapeutics-nets

## Connected records

- technologies: [Gamma-delta T cell therapy](https://onco.cc/technologies/gamma-delta-t-cell-therapy/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [Somatostatin receptor 2](https://onco.cc/targets/sstr2/)
- companies: [Expression Therapeutics](https://onco.cc/companies/expression-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/adept-star-net-1.json